

Azole-resistant *Aspergillus fumigatus*, Iran


Technical Appendix

Technical Appendix Table 1. Distribution of azole-resistant and azole-susceptible *Aspergillus fumigatus* isolates, Iran, 2003–2009

Year of isolation	No. isolates with each phenotype and resistance mechanism		
	Wild type	Resistant, TR ₃₄ /L98H	Resistant, non-TR ₃₄ /L98H
2003	11	—	—
2004	18	—	—
2005	11	1	—
2006	17	—	—
2007	19	2	1
2008	20	—	—
2009	24	—	—
Total	120	3	1

Technical Appendix Table 2. First reports of multiple-triazole-resistant *Aspergillus fumigatus* isolate(s) carrying the TR₃₄/L98H mutations in the CYP51A gene, by country

Region/Country	First reported TR ₃₄ /L98H <i>A.fumigatus</i> isolate(s)	Reference
Europe	Netherlands	1998
	UK	1999
	Norway	2001
	Spain	2002/2003
	Denmark	2007
	Belgium	2008
	France	2010/2011
	Germany	2012
Asia	Iran	2005
	India	2008
	China	2008/2009



Technical Appendix Figure. Minimum spanning tree comparing genotypic relatedness of clinical azole-resistant *Aspergillus fumigatus* isolates carrying TR₃₄/L98H alteration in the CYP51A gene from Iran with those reported from European countries. Microsatellite typing of 6 STR loci demonstrated identical patterns for two of the three azole-resistant isolates from Iran, but the TR₃₄/L98H isolates from Iran did not cluster with those from the Netherlands and other European countries, indicating no close genetic relatedness. Each circle corresponds to a unique genotype, and each color indicates the origin of azole-resistant TR₃₄/L98H isolates: red, Iran (n = 3); green, the Netherlands (n = 20); blue, other European countries (n = 24). The size of the circle corresponds to the number of isolates with that genotype. Connecting lines correspond to the number of different microsatellite loci between the genotypes: solid thick and thin branches indicate 1 and 2 microsatellite marker differences, respectively; dashed branches indicate 3 microsatellite marker difference; dotted branches indicate ≥4 microsatellite marker differences between genotypes.

References

1. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in *Aspergillus fumigatus* and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. [PubMed](http://dx.doi.org/10.1371/journal.pmed.0050219) <http://dx.doi.org/10.1371/journal.pmed.0050219>
2. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of azole resistance in *Aspergillus fumigatus* associated with treatment failure. Emerg Infect Dis. 2009;15:1068–76. [PubMed](http://dx.doi.org/10.3201/eid1507.090043) <http://dx.doi.org/10.3201/eid1507.090043>

3. Mellado E, De La Camara R, Buendia B, Rodriguez-Tudela JL, Cuenca-Estrella M. Breakthrough pulmonary *Aspergillus fumigatus* infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. *Rev Iberoam Micol.* 2013;30:64–8. [PubMed](#)
<http://dx.doi.org/10.1016/j.riam.2012.09.002>
4. Mortensen KL, Jensen RH, Johansen HK, Skov M, Pressler T, Howard SJ, et al. *Aspergillus* species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on *Aspergillus fumigatus* azole resistance. *J Clin Microbiol.* 2011;49:2243–51. [PubMed](#) <http://dx.doi.org/10.1128/JCM.00213-11>
5. Lagrou K, Vleeschouwer J, Meersseman W, Dupont L, Verleden GM, Melchers WJG, et al., editors. Triazole resistance among clinical *Aspergillus fumigatus* isolates. 3rd Adv Against Aspergillosis. 2008; 16–19 January 2008; Miami, FL.
6. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, et al. High prevalence of azole-resistant *Aspergillus fumigatus* in adults with cystic fibrosis exposed to itraconazole. *Antimicrob Agents Chemother.* 2012;56:869–74. [PubMed](#) <http://dx.doi.org/10.1128/AAC.05077-11>
7. Morio F, Aubin GG, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D, et al. High prevalence of triazole resistance in *Aspergillus fumigatus*, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. *J Antimicrob Chemother.* 2012;67:1870–3. [PubMed](#) <http://dx.doi.org/10.1093/jac/dks160>
8. Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. First reported case of azole-resistant *Aspergillus fumigatus* due to the TR/L98H mutation in Germany. *Antimicrob Agents Chemother.* 2012;56:6060–1. [PubMed](#) <http://dx.doi.org/10.1128/AAC.01017-12>
9. Chowdhary A, Kathuria S, Xu J, Sharma C, Sundar G, Singh PK, et al. Clonal expansion and Emergence of environmental multiple-triazole-resistant *Aspergillus fumigatus* strains carrying the TR(34)/L98H mutations in the *cyp51A* gene in India. *PLoS ONE.* 2012;7:e52871. [PubMed](#) <http://dx.doi.org/10.1371/journal.pone.0052871>
10. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant *Aspergillus fumigatus* strains carrying the TR/L98H mutations in the *cyp51A* gene in India. *J Antimicrob Chemother.* 2012;67:362–6. [PubMed](#)
<http://dx.doi.org/10.1093/jac/dkr443>

11. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in *Aspergillus fumigatus* isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. *Antimicrob Agents Chemother*. 2011;55:4465–8.
[PubMed http://dx.doi.org/10.1128/AAC.00185-11](http://dx.doi.org/10.1128/AAC.00185-11)